Clinical trial • Phase I • Neurology|Musculoskeletal
TNV108 for Diabetic peripheral neuropathy
Phase I trial of TNV108 for Diabetic peripheral neuropathy. 108 participants.
Overview
- Trial Therapeutic Area
- Neurology|Musculoskeletal
- Trial Disease
- Diabetic peripheral neuropathy
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 12-01-2026
- First CTIS Authorization Date
- 24-02-2026
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 108
Recruitment
- Planned Sample Size
- 108
- Recruitment Window Months
- 21
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 108
Netherlands
- Earliest CTIS Part Ii Submission Date
- 12-02-2026
- Latest Decision Or Authorization Date
- 24-02-2026
- Processing Time Days
- 12
- Number Of Sites
- 1
- Number Of Participants
- 108
Sites
- Site Name
- Centre for Human Drug Research
- Department Name
- Neurology
- Contact Person Name
- Marieke Niesters
- Contact Person Email
- clintrials@chdr.nl
- Number Of Participants
- 108
Sponsor
Primary sponsor
- Full Name
- Tenvie Therapeutics Inc.
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- TNV108
Related trials
Other published trials that may interest you.
- RIMONABANT for Spinal cord injury|Cervical spinal cord injury
- MEXILETINE HYDROCHLORIDE for Myotonic dystrophy type 1 | Myotonic dystrophy type 2
- Triamcinolone Hexacetonide for Carpal tunnel syndrome
- H-L-TRYPHOPHANYL-L-SERYL-GLYCYL-L-TRYPTOPHANYL-L-SERYL-L-SERYL-L-CYSTEINYL-L-SERYL-L-ARGINYL-L-SERYL-L-CYSTEINYL-GLYCYL-OH (DISULFIDE BOND), ACETATE SALT for Amyotrophic lateral sclerosis (ALS)
- Mexiletine hydrochloride for Myotonic dystrophy type 1|Myotonic dystrophy type 2